Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis

Susanna Esposito, Fabrizia Corona, Luisa Barzon, Federica Cuoco, Laura Squarzon, Giorgia Marcati, Marta Torcoletti, Monia Gambino, Giorgio Palù, Nicola Principi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.

Original languageEnglish
Pages (from-to)1387-1393
Number of pages7
JournalExpert Review of Vaccines
Volume13
Issue number11
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Papillomavirus Vaccines
Juvenile Arthritis
Safety
Neutralizing Antibodies
Vaccines
Joints

Keywords

  • autoimmune disease
  • bivalent papillomavirus vaccine
  • HPV
  • juvenile idiopathic arthritis
  • papillomavirus vaccine
  • rheumatological disease

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. / Esposito, Susanna; Corona, Fabrizia; Barzon, Luisa; Cuoco, Federica; Squarzon, Laura; Marcati, Giorgia; Torcoletti, Marta; Gambino, Monia; Palù, Giorgio; Principi, Nicola.

In: Expert Review of Vaccines, Vol. 13, No. 11, 01.11.2014, p. 1387-1393.

Research output: Contribution to journalArticle

Esposito, S, Corona, F, Barzon, L, Cuoco, F, Squarzon, L, Marcati, G, Torcoletti, M, Gambino, M, Palù, G & Principi, N 2014, 'Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis', Expert Review of Vaccines, vol. 13, no. 11, pp. 1387-1393. https://doi.org/10.1586/14760584.2014.943195
Esposito, Susanna ; Corona, Fabrizia ; Barzon, Luisa ; Cuoco, Federica ; Squarzon, Laura ; Marcati, Giorgia ; Torcoletti, Marta ; Gambino, Monia ; Palù, Giorgio ; Principi, Nicola. / Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. In: Expert Review of Vaccines. 2014 ; Vol. 13, No. 11. pp. 1387-1393.
@article{8e62d8077c4046869c7d90245dc7a960,
title = "Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis",
abstract = "Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.",
keywords = "autoimmune disease, bivalent papillomavirus vaccine, HPV, juvenile idiopathic arthritis, papillomavirus vaccine, rheumatological disease",
author = "Susanna Esposito and Fabrizia Corona and Luisa Barzon and Federica Cuoco and Laura Squarzon and Giorgia Marcati and Marta Torcoletti and Monia Gambino and Giorgio Pal{\`u} and Nicola Principi",
year = "2014",
month = "11",
day = "1",
doi = "10.1586/14760584.2014.943195",
language = "English",
volume = "13",
pages = "1387--1393",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis

AU - Esposito, Susanna

AU - Corona, Fabrizia

AU - Barzon, Luisa

AU - Cuoco, Federica

AU - Squarzon, Laura

AU - Marcati, Giorgia

AU - Torcoletti, Marta

AU - Gambino, Monia

AU - Palù, Giorgio

AU - Principi, Nicola

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.

AB - Aims: To evaluate the immunogenicity, safety and tolerability of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis (JIA). Methods: Twenty-one patients with JIA aged 12-25 years and 21 healthy controls were enrolled and received three doses of the bivalent HPV vaccine. Results: All of the subjects were seronegative at baseline and seroconverted after the scheduled doses. The JIA patients showed significantly lower HPV16 neutralising antibody titres than controls 1 month after the administration of the third dose (p <0.05), whereas no significant difference was observed in HPV18 neutralising antibody titres. Local and systemic reactions were similarly frequent in the patients and controls, and there were no significant changes in 27-joint juvenile arthritis disease activity score or laboratory tests. Conclusion: The bivalent HPV vaccine is safe in patients with stable JIA and regardless of the use of medications the vaccine assures an adequate degree of protection for a certain time.

KW - autoimmune disease

KW - bivalent papillomavirus vaccine

KW - HPV

KW - juvenile idiopathic arthritis

KW - papillomavirus vaccine

KW - rheumatological disease

UR - http://www.scopus.com/inward/record.url?scp=84911475847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911475847&partnerID=8YFLogxK

U2 - 10.1586/14760584.2014.943195

DO - 10.1586/14760584.2014.943195

M3 - Article

VL - 13

SP - 1387

EP - 1393

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 11

ER -